IL2 and neoplasm: These calcineurin inhibitors act by reducing interleukin-2 expression, inhibit the early activation of T lymphocytes (that is, the transition from the G0 to the G1 phase of the cell cycle) and promote tumor cell cycle progression by increasing cdk4 kinase activity [26,27].